Article

Biology Chemistry - Patents

Antibody patenting: Plasseraud IP contributes to a comprehensive guide on the subject

Book

18 August, 2019

Written by Cyra Nargolwalla and Isabelle Labarre

Antibodies are necessary tools in medicine and biotechnology, they are used in therapy, diagnostics, analytics, and research. Which types of antibody inventions are patent-eligible? How to draft a patent? How to claim it? Which pitfalls must be avoided in defining an antibody? Cyra Nargolwalla, Partner at Plasseraud IP, and Isabelle Labarre, Patent Attorney, provide their advice on these and other topics in the AIPPI’s edition: Antibody Patenting: A Practioner’s Guide to Drafting, Prosecution and Enforcement. This book covers 23 of the most important IP jurisdictions worldwide, including France.

For more information: Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement

On the same expertise
By the same author

On the same expertise

Supplementary Protection Certificates (SPC): a new IP right to come?

22 February, 2022

Isabelle Labarre

This article is also available in French. In January 2022, the UP/UPC (Unitary Patent and Unified Patent Court) took a major step toward its entry (...)

Patent Term Extension in China is now possible for pharmaceutical patents

20 January, 2022

Isabelle Labarre

On June 01, 2021, the fourth amendment of Patent Law in China entered into effect. This amendment includes significant changes, such as the (...)

Artificial Intelligence and Drug Development from a patent perspective

24 March, 2021

Mathias Robert

Artificial Intelligence and Drug Development

Artificial intelligence (AI), like any other previous General Purpose Technology, is pervasive, improves over time and spans complementary (...)

EPO Approach to Priority Entitlement: Clarification by Recent Board of Appeal decision

13 January, 2021

Hélène Leblois-Prehaud

While claiming priority in the US or other countries outside Europe may not be a sensitive issue, there are potentially deadly pitfalls in claiming (...)

Personalised medicine claims in Europe

1 July, 2020

Clémentine Eap

Personalised medicine is considered as the future of healthcare. It aims at providing therapies tailored to each patient’s individual profile so as (...)

Sufficient Disclosure/Written Description: the end of the « antibody » exception in the United States

29 June, 2018

Isabelle Magnin-Feysot

Suffisance de description : la fin de l’exception « anticorps » aux Etats-Unis

An antibody can traditionally be described in multiple ways: According to the functional definition, an antibody is classically defined by its (...)

Brazil: the Patent & Trademark Office reducing the backlog for Patents

14 May, 2018

Nathalie Wajs

Brésil : comment l'Office envisage de réduire drastiquement le backlog dans l'examen des demandes de brevet

How the Brazilian Patent and Trademark Office (BPTO) envisions making drastic reductions in the backlog of examination of patent applications During (...)

On the same expertise

Supplementary Protection Certificates (SPC): a new IP right to come?

Article

19 March, 2021

Isabelle Labarre, Catherine Touati

This article is also available…

(...)

Patent Term Extension in China is now possible for pharmaceutical patents

Newsletter January 2022

11 January, 2022

Isabelle Labarre

On June 01, 2021, the fourth amendment of Patent Law in China entered into effect.

This amendment includes significant changes, such as…

(...)

How has the Covid-19 pandemic affected oral proceedings before the EPO?

Newsletter September 2020

7 September, 2020

Jacqueline Vinatier , Cyra Nargolwalla

In view of the present situation with Coronavirus (Covid-19), the European Patent Office is adopting the following preventive measures regarding…

(...)

Supplementary protection certificate (SPC) and new therapeutic applications: Where do we stand?

Newsletter September 2020

24 March, 2021

Isabelle Labarre, Catherine Touati

A supplementary protection certificate (SPC) is an IP right which extends the duration of the patent granted for an active ingredient of a…

(...)

Comment on the recently published EPO statistics

26 June, 2017

Isabelle Labarre

Over the last few months, several patent offices have published their annual reports. The statistics published by the European Patent Office (EPO…

(...)

On the same expertise

Supplementary Protection Certificates (SPC): a new IP right to come?

22 February, 2022

Isabelle Labarre

This article is also available in French. In January 2022, the UP/UPC (Unitary Patent and Unified Patent Court) took a major step toward its entry (...)

Patent Term Extension in China is now possible for pharmaceutical patents

20 January, 2022

Isabelle Labarre

On June 01, 2021, the fourth amendment of Patent Law in China entered into effect. This amendment includes significant changes, such as the (...)

Artificial Intelligence and Drug Development from a patent perspective

24 March, 2021

Mathias Robert

Artificial intelligence (AI), like any other previous General Purpose Technology, is pervasive, improves over time and spans complementary (...)

EPO Approach to Priority Entitlement: Clarification by Recent Board of Appeal decision

13 January, 2021

Hélène Leblois-Prehaud

While claiming priority in the US or other countries outside Europe may not be a sensitive issue, there are potentially deadly pitfalls in claiming (...)

Personalised medicine claims in Europe

1 July, 2020

Clémentine Eap

Personalised medicine is considered as the future of healthcare. It aims at providing therapies tailored to each patient’s individual profile so as (...)

Sufficient Disclosure/Written Description: the end of the « antibody » exception in the United States

29 June, 2018

Isabelle Magnin-Feysot

An antibody can traditionally be described in multiple ways: According to the functional definition, an antibody is classically defined by its (...)

Brazil: the Patent & Trademark Office reducing the backlog for Patents

14 May, 2018

Nathalie Wajs

How the Brazilian Patent and Trademark Office (BPTO) envisions making drastic reductions in the backlog of examination of patent applications During (...)

*Périmètre

X

X

Antibody patenting: Plasseraud IP contributes to a comprehensive guide on the subject

X